GlassScriptPhysician profile
Timothy K Flannery
NPI 1871662304
$31,773.49
in general payments reported to CMS, 2019-2025
37 companies · $983 in 2025
The $983 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,322 · 2020: $398 · 2021: $374 · 2022: $8,150 · 2023: $7,493 · 2024: $12K · 2025: $983.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $3,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $17,226.00 |
| Food and Beverage | $3,303.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascendis Pharma Endocrinology INC | $26,454.78 | 2022-2025 | Skytrofa |
| Novo Nordisk As | $1,388.80 | 2019 | |
| Novo Nordisk INC | $710.68 | 2019-2025 | Sogroya, Wegovy |
| Abbvie INC. | $358.84 | 2019-2025 | |
| Tandem Diabetes Care, INC. | $246.27 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Kyowa Kirin, INC. | $218.03 | 2023-2025 | Crysvita |
| Lilly USA, LLC | $202.11 | 2019-2023 | Baqsimi |
| Tolmar, INC. | $190.58 | 2023-2024 | |
| Abbott Laboratories | $180.99 | 2019-2021 | |
| Dexcom, INC. | $171.59 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $155.68 | 2024-2025 | |
| Arbor Pharmaceuticals, INC. | $152.02 | 2019-2022 | |
| Pfizer INC. | $140.20 | 2019-2025 | |
| Xeris Pharmaceuticals, INC. | $112.53 | 2021-2023 | Gvoke Hypopen |
| Medtronic, INC. | $105.34 | 2022-2023 | Minimed 780g, Inpen Smart Insulin Delivery System |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $88.94 | 2023-2025 | Triptodur, Triptodur |
| Rhythm Pharmaceuticals, INC. | $85.97 | 2022-2023 | Imcivree |
| Tolmar Pharmaceuticals, INC. | $84.00 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $83.92 | 2019-2020 | |
| Insulet Corporation | $75.28 | 2019-2022 | |
| Horizon Therapeutics Plc | $74.38 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $60.00 | 2020 | |
| Sandoz INC. | $48.94 | 2019 | |
| Eton Pharmaceuticals, INC. | $48.66 | 2023-2025 | Alkindi, Increlex, Khindivi |
| Ascensia Diabetes Care US INC. | $43.52 | 2019 | |
| Becton, Dickinson and Company | $41.96 | 2022 | |
| Medtronic Minimed, INC. | $33.66 | 2019-2020 | |
| Chiesi USA, INC. | $30.22 | 2024 | Myalept |
| Sequel Med Tech, LLC | $26.15 | 2025 | Twiist |
| Biomarin Pharmaceutical INC. | $24.00 | 2022 | |
| Endo Pharmaceuticals INC. | $23.26 | 2022 | |
| Alexion Pharmaceuticals, INC. | $22.61 | 2019 | |
| Travere Therapeutics, INC. | $21.60 | 2019 | |
| Genzyme Corporation | $18.23 | 2019 | |
| Vistapharm, INC. | $17.72 | 2021 | |
| Senseonics, Incorporated | $17.00 | 2019 | |
| Mannkind Corporation | $15.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Flannery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.